Corient Private Wealth LLC Purchases 4,253 Shares of ICU Medical, Inc. $ICUI

Corient Private Wealth LLC lifted its position in ICU Medical, Inc. (NASDAQ:ICUI) by 104.8% during the fourth quarter, Holdings Channel reports. The institutional investor owned 8,312 shares of the medical instruments supplier’s stock after buying an additional 4,253 shares during the quarter. Corient Private Wealth LLC’s holdings in ICU Medical were worth $1,189,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Hilton Head Capital Partners LLC acquired a new stake in shares of ICU Medical in the 4th quarter worth $32,000. Covestor Ltd boosted its holdings in ICU Medical by 22.1% in the fourth quarter. Covestor Ltd now owns 696 shares of the medical instruments supplier’s stock worth $99,000 after acquiring an additional 126 shares in the last quarter. Strs Ohio boosted its holdings in ICU Medical by 60.0% in the fourth quarter. Strs Ohio now owns 800 shares of the medical instruments supplier’s stock worth $114,000 after acquiring an additional 300 shares in the last quarter. Kemnay Advisory Services Inc. purchased a new stake in shares of ICU Medical during the fourth quarter worth about $120,000. Finally, Smartleaf Asset Management LLC grew its stake in shares of ICU Medical by 11.6% during the second quarter. Smartleaf Asset Management LLC now owns 969 shares of the medical instruments supplier’s stock worth $128,000 after acquiring an additional 101 shares during the last quarter. Institutional investors own 96.10% of the company’s stock.

Insiders Place Their Bets

In related news, VP Virginia Ruth Sanzone sold 2,447 shares of the firm’s stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $124.08, for a total transaction of $303,623.76. Following the sale, the vice president owned 19,460 shares in the company, valued at approximately $2,414,596.80. This trade represents a 11.17% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director David C. Greenberg sold 2,424 shares of the stock in a transaction dated Tuesday, May 12th. The stock was sold at an average price of $122.91, for a total transaction of $297,933.84. Following the sale, the director directly owned 7,960 shares in the company, valued at approximately $978,363.60. The trade was a 23.34% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Corporate insiders own 2.10% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently commented on ICUI shares. KeyCorp decreased their price objective on shares of ICU Medical from $180.00 to $164.00 and set an “overweight” rating for the company in a research report on Monday, April 27th. Needham & Company LLC upgraded shares of ICU Medical from a “hold” rating to a “buy” rating and set a $165.00 price target on the stock in a research note on Wednesday, May 27th. Piper Sandler decreased their price target on shares of ICU Medical from $178.00 to $163.00 and set an “overweight” rating for the company in a report on Friday, April 17th. Sanford C. Bernstein downgraded shares of ICU Medical to a “market perform” rating in a research note on Monday, June 15th. Finally, Zacks Research raised shares of ICU Medical from a “hold” rating to a “strong-buy” rating in a report on Monday. Three research analysts have rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $168.40.

ICU Medical Trading Up 1.3%

Shares of NASDAQ:ICUI opened at $148.46 on Thursday. The company has a current ratio of 2.34, a quick ratio of 1.17 and a debt-to-equity ratio of 0.60. ICU Medical, Inc. has a 12-month low of $107.00 and a 12-month high of $160.29. The business has a 50 day moving average of $132.62 and a two-hundred day moving average of $138.43. The company has a market capitalization of $3.71 billion, a PE ratio of 80.25, a PEG ratio of 2.05 and a beta of 0.76.

ICU Medical (NASDAQ:ICUI) last issued its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.97 EPS for the quarter, topping analysts’ consensus estimates of $1.78 by $0.19. The business had revenue of $525.77 million for the quarter, compared to analysts’ expectations of $520.65 million. ICU Medical had a net margin of 2.15% and a return on equity of 7.50%. The business’s revenue was down 12.3% on a year-over-year basis. During the same quarter last year, the company earned $1.72 EPS. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. As a group, analysts forecast that ICU Medical, Inc. will post 6.5 EPS for the current year.

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.